Amgen: Not An Investment Mistake, But It Was Better Before
Amgen could report great quarterly results with revenue, operating income and EPS growing with a solid pace. The stock is undervalued in my opinion and Amgen could be seen as a good investment. How...
Call of the day: The health care trade
CNBC's Halftime traders Steve Weiss, Liz Young, Joe Terranova, and Brian Belski discuss the call of the day: health care.
Amgen (AMGN) Stock Outperforms Industry YTD: Here's Why
Amgen (AMGN) expects strong sales growth of products like Tezspire, Evenity and Repatha to be offset by lower revenues from oncology biosimilars and Enbrel.
The FTC cleared Amgen's $27.8 billion Horizon buyout — here's what it means for other massive pharma deals
Some analysts and M&A experts say the settlement agreement doesn't mean that the FTC will stop baring its teeth at other large buyouts in the industry.
Analysis: FTC settlement could shelter Amgen from US price cuts, taxes
The U.S. Federal Trade Commission's decision on Friday to allow Amgen's takeover of Horizon Therapeutics was the latest setback to its stated goal of stricter antitrust enforcement, and instead pav...
FTC Allows Amgen (AMGN) to Proceed With $28B Horizon Buyout
Per the settlement terms, Amgen (AMGN) is prohibited from bundling its products with Horizon's Tepezza or Krystexxa. Amgen expects to complete the Horizon acquisition before 2023-end.
Amgen gets green light from FTC for $27.8B Horizon Therapeutics deal
The Federal Trade Commission will allow Amgen to continue a $27.8 billion purchase of Horizon Therapeutics. The companies anticipate closing the deal in the fourth quarter.
Amgen settles with the FTC over $28 billion deal
The Federal Trade Commission will allow pharmaceutical giant Amgen to move ahead with its acquisition of Horizon Therapeutics, averting a trial set for September.
FTC clears Amgen's $28 billion acquisition of Horizon Therapeutics
Shares of Horizon Therapeutics PLC (NASDAQ: HZNP) are trading materially up today after the FTC allowed Amgen Inc (NASDAQ: AMGN) to move forward with its $27.8 billion acquisition of the biopharmac...
As Medicare drug-price negotiations inch forward, some states are flexing new powers to cut costs for a broader swath of drugs
As Medicare's years-long drug-price negotiation process is being hotly debated and litigated, some states are plowing ahead with wide-ranging efforts to bring down costs for a potentially much broa...
Amgen's $27.8 Billion Purchase Of Horizon Therapeutics On After FTC Settlement
The agency previously argued the merger could harm patients who are prescribed Horizon's two fastest-growing drugs.
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen, Horizon Therapeutics Stocks Rise After FTC Settlement Over $27.8 Billion Merger
The Federal Trade Commission makes provision that prohibits “bundling” discounts for some medications.
FTC allows Amgen to move forward with $27.8 billion Horizon Therapeutics deal
CNBC's Emily Wilkins joins 'Squawk Box' with the latest news.
FTC settles with Amgen over $27.8 billion takeover of Horizon Therapeutics
The Federal Trade Commission reached a deal with Amgen Inc. AMGN, -0.60% to approve its $27.8 billion acquisition of Horizon Therapeutics plc, HZNP, -0.07% the agency announced Friday.
Related Companies